YARROW BIOSCIENCE, INC. Payments of Stock Issuance Costs
YARROW BIOSCIENCE, INC. (YARW) reported Payments of Stock Issuance Costs of $135.00 thousand for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2023-05-11
- YARROW BIOSCIENCE, INC. payments of stock issuance costs for the quarter ending 2022-06-30 was $87.00K.
- YARROW BIOSCIENCE, INC. payments of stock issuance costs for the quarter ending 2022-03-31 was $48.00K, a 98.80% decline year-over-year.
- YARROW BIOSCIENCE, INC. payments of stock issuance costs for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- YARROW BIOSCIENCE, INC. payments of stock issuance costs for the quarter ending 2021-09-30 was -$814.00K.
- YARROW BIOSCIENCE, INC. payments of stock issuance costs for fiscal 2021 was $3.18M, a 23.46% decline from fiscal 2020.
- YARROW BIOSCIENCE, INC. payments of stock issuance costs for fiscal 2020 was $4.15M, a 1056.27% increase from fiscal 2019.
- YARROW BIOSCIENCE, INC. payments of stock issuance costs for fiscal 2019 was $359.00K, a 820.51% increase from fiscal 2018.
- YARROW BIOSCIENCE, INC. payments of stock issuance costs for fiscal 2018 was $39.00K.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month | Payments of Stock Issuance Costs 12 month as first filed |
|---|---|---|---|---|---|
| 2022-06-30 | $87.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $135.00K 10-Q · filed 2022-08-12 | $135.00K derived: sum of 3 quarters · filed 2023-05-11 | -$679.00K derived: sum of 4 quarters · filed 2023-05-11 | |
| 2022-03-31 | $48.00K 10-Q · filed 2023-05-11 | $48.00K derived: sum of 2 quarters · filed 2023-05-11 | -$766.00K derived: sum of 3 quarters · filed 2023-05-11 | -$766.00K derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$814.00K derived: sum of 2 quarters · filed 2023-03-14 | -$814.00K derived: sum of 3 quarters · filed 2023-03-14 | $3.18M 10-K · filed 2023-03-14 | $4.21M 10-K · filed 2022-03-17 |
| 2021-09-30 | -$814.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$814.00K derived: sum of 2 quarters · filed 2022-11-14 | $3.18M 10-Q · filed 2022-11-14 | $3.42M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $3.99M 10-Q · filed 2022-08-12 | $4.24M derived: sum of 3 quarters · filed 2022-08-12 | $4.24M derived: sum of 4 quarters · filed 2022-08-12 | |
| 2021-03-31 | $3.99M 10-Q · filed 2022-05-12 | $4.24M derived: sum of 2 quarters · filed 2022-05-12 | $4.24M derived: sum of 3 quarters · filed 2022-05-12 | $8.14M derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | $248.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $248.00K derived: sum of 2 quarters · filed 2022-03-17 | $4.15M derived: sum of 3 quarters · filed 2022-03-17 | $4.15M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $3.90M derived: sum of 2 quarters · filed 2021-08-12 | $3.90M 10-Q · filed 2020-11-05 | ||
| 2020-06-30 | $3.90M 10-Q · filed 2021-08-12 | $3.90M 10-Q · filed 2020-08-06 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $359.00K derived: sum of 2 quarters · filed 2021-03-04 | $359.00K 10-K · filed 2021-03-04 | ||
| 2019-09-30 | $359.00K 10-Q · filed 2020-11-05 | $359.00K 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $39.00K 10-K · filed 2021-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |